Conversely, pharmacological stabilizers of HIF-1α (PHD inhibitors) are in clinical development for treatment of anemia [26,27], and the potential for repositioning such drugs as “innate immune boosters” has been explored in animal models of bacterial infection. Here, HIF1A is linked to anemia.